This investor's guide unveils the top three gene editing technologies—CRISPR, Base Editing, and Prime Editing—poised for explosive growth by mid-2026, offering crucial insights for strategic biotech investment decisions.
The Q1 2026 US Biotech Investor Forums highlighted significant shifts towards precision medicine, AI integration, and sustainable funding models, underscoring a robust yet evolving investment landscape for strategic growth.